We are a team of scientists with broad backgrounds ranging from molecular and chemical biology, genomics, epigenetics, and cell biology, to computational biology, statistical modeling, and machine learning, who are passionate about using our groundbreaking biological and computational technologies for enhancing human health and drug discovery.
Nir is a Professor of Computer Science and of Life Sciences at the Hebrew University of Jerusalem. His major research interests include Systems Biology, Gene Regulatory Networks, Computational Biology, and Probabilistic Graphical Models.
Prof. Friedman pioneered the use of probabilistic graphical models in reverse engineering of regulatory networks from high-throughput biological assays. In the last decade he shifted his focus to studying molecular mechanisms of transcription and chromatin by combination of novel high-throughput experiments and analysis. He examines these questions both in basic science context and in application to medical diagnosis and decision-making. Prof. Friedman has published more than 150 papers in peer-reviewed journals and conferences. He is the recipient of multiple awards, including the Michael Bruno Memorial Award (Yad Hanadiv), the Alexander von Humboldt Research Award, and two Advanced Researcher ERC grants. Prof. Friedman co-authored a widely used textbook on probabilistic graphical models. He is a fellow of the International Society for Computational Biology and a past President of the Israeli Society for Computational Biology and Bioinformatics and served as the Lead PI and Coordinator of a multi-PI Israeli Center of Research Excellence (I-CORE).
Ronen has over 20 years of experience in academic research in the fields of genomics and epigenetics, protein homeostasis, cell biology, biochemistry, and molecular biology. He did his PhD at the Technion, Israel under the supervision of Nobel laureate Aaron Ciechanover.
Following his postdoctoral research fellowship at the Allis lab for chromatin biology and epigenetics at Rockefeller University, NYC, he moved to the Hebrew University of Jerusalem. There he developed, together with Prof. Nir Friedman, the cell-free ChIP-seq technology. In 2020 Ronen co-founded Senseera to make cfChIP-seq accessible to patients.
Israa holds a PhD in Biochemistry and Molecular biology from the Hebrew University in Jerusalem. She then joined the Friedman lab as a postdoctoral researcher, where she extended the development of the cfChIP-seq assays and applied them to multiple medical questions.
Following her post-doctoral fellowship she co-founded Senseera aiming to apply her profound understanding and expertise in genomics assays and experimental knowledge to develop the technology into a cutting-edge diagnostic assay.
Jenia holds a PhD in computer science and computational biology from the Hebrew university in Jerusalem. He has wide experience in the fields of data science, machine learning, bioinformatics and computational genomics.
During his research he established a sophisticated high-throughput system for phenotyping the effect of thousands of gene mutations on transcriptional responses. This system involved state of the art liquid handling robotics, high-throughput microscopy and flow cytometry, and development of new statistical and analysis methodologies. He subsequently spearheaded the development of analysis methods for new sequencing based genomic and epigenomics assays. Jenia co-founded Senseera aiming to apply his vast computational experience and intimate understanding of epigenetic assays to develop the new generation of liquid-biopsy assays for precise and accessible health monitoring.
Daniella brings over ten years of experience in pharmaceutical API global marketing at Teva Pharmaceuticals. She also brings strong operational background in biobanking and clinical trials as the founding manager of Israel's first and only population-based research biobank "TIPA" within Israel’s healthcare insurer/provider Maccabi Healthcare Services.
Daniella joined Senseera in 2021 to oversee the entire operational activities of the company, lead the clinical trials activity and promote strategic and BD activities.
Prof. Galun is a full professor at the Hebrew University, and was until recently the Director of the Gene and Cell Therapy Institute, which he established in 1998 at Hadassah Hebrew University Hospital. Beyond his rich clinical career and academic record, Prof. Galun was founder of a company that developed monoclonal antibodies to treat hepatitis B and C patients.
He developed a novel therapy for pancreatic cancer based on siRNA targeting K-Ras for which he established Silenseed, which is now ending phase II. He developed the FIV based delivery system for gene therapy and also developed new therapeutic targets for liver cancer. Established novel imaging technologies for the identification of liver pathology. He established a GMP level production facility with four clear rooms engaged in the production of biological materials administered to humans in phase I/II/III studies. Received in recent years numerous prestigious grants including Advance ERC, NIH, ISF, SFB-DFG, and other large grants. Until today he published >200 peer review papers in Nature, Nature Medicine and other leading journals.
Recipient of the 2006 Nobel Prize in Chemistry, Prof. Roger D. Kornberg serves as the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. Prof. Kornberg’s award winning research centered on the process by which DNA is converted into RNA. He also discovered the basic subunit of chromatin, the nucleosome and its relation to transcriptional regulation.
Beyond the Nobel prize, Prof. Kornberg won numerous awards including the 2001 Welch Prize, and the 2002 Leopold Mayer prize and he is a member of the U.S. National Academy of Sciences, and served on the Scientific Advisory Boards of several biotech companies.